Seer delivered a solid second quarter in 2025, achieving $4.1 million in revenue, a 32% increase year-over-year, primarily driven by higher product sales and service revenue. The company also launched key new products, the Proteograph ONE assay and SP200 automation instrument, enhancing platform scalability. Despite macroeconomic pressures, Seer ended the quarter with strong cash reserves and reduced operating expenses.
Revenue for Q2 2025 reached $4.1 million, marking a 32% increase compared to the same period last year.
The company launched the new high-throughput Proteograph ONE assay and SP200 automation instrument, significantly improving platform scalability and efficiency.
Net loss for the quarter was $19.4 million, an improvement from $22.9 million in the prior year period.
Seer maintained a strong cash position, ending the quarter with approximately $263.3 million in cash, cash equivalents, and investments.
Seer reiterates its full-year 2025 revenue guidance, expecting it to be in the range of $17 million to $18 million, representing a 24% growth at the midpoint compared to full-year 2024.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance